Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

利福定胶囊 - NMPA Drug Approval Details

Approvals/NMPA/Rifandine Capsules

Approved

化学药品

Rifandine Capsules

淮南泰复制药有限公司🇨🇳 National Medical Products Administration

Approval Date: Dec 18, 2002
Approval ID: 7zz22bdboY8
Company: 淮南泰复制药有限公司
Type: 化学药品

Approval Details

Approval Id: 7zz22bdboY8
Approval Number: 国药准字H34022219
Generic Name: 利福定胶囊
Generic Name En: Rifandine Capsules
Drug Type: 化学药品
Strength: 0.15g
Reg Date: 2002-12-18
Company Name: 淮南泰复制药有限公司
Production Company Address: 安徽淮南经济技术开发区
Company Detail Path: /organization/huai-nan-tai-fu-zhi-yao-you-xian-gong-si

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 18, 2002

Approval ID

7zz22bdboY8

Type

化学药品

Back to NMPA Approvals